The Wellcome Sanger Institute, Helmholtz Munich, and Parse Biosciences are collaborating to create a comprehensive single-cell atlas profiling cancer plasticity and treatment response. The initiative intends to generate extensive RNA sequencing data from tumor organoid cultures, facilitating AI-driven models for drug response prediction. This large-scale dataset aims to deepen understanding of tumor adaptability and support precision oncology development.